Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11735472 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL11739586 | 0.89 | ALDH1A1 (0.46) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL27187234 | 0.85 | TAAR1 (0.41) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL27187239 | 0.85 | TAAR1 (0.41) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL30852319 | 0.85 | ALDH1A1 (0.38) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL27188081 | 0.84 | PRKDC (0.41) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL27187259 | 0.84 | ALDH1A1 (0.39) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL27188085 | 0.84 | PRKDC (0.41) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL27187311 | 0.84 | MAPT (0.40) | ALDH1A1KDM4ETDP1MAPTCYP3A4 | |
| SCHEMBL27187308 | 0.84 | MAPT (0.40) | ALDH1A1KDM4ETDP1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2024073601-A2 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240109836-A1 | NON-HALLUCINOGENIC ARIADNE ANALOGS FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-04 | — | — | US | disclosed |
| CN-117642379-A | Phenylalkylamines and methods of making and using the same | 吉尔伽美什制药公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4305019-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022204323-A1 | NON-HALLUCINOGENIC ARIADNE ANALOGS FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022192781-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109836-A1 | NON-HALLUCINOGENIC ARIADNE ANALOGS FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HTR2C, HTR3A, CNR2 | ALDH1A1 1723/4885KDM4E 2929/4885TDP1 3773/4885 |
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | ALDH1A1 1077/4885KDM4E 988/4885TDP1 571/4885 |
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | ATXN2, HCRTR2, CDR2 | ALDH1A1 402/4885KDM4E 4634/4885TDP1 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.